$80K — $100K *
We are the leading technology provider for antibody-based drug discovery, focusing solely on our partners without pursuing an internal product pipeline. Since 2009, we have partnered with over 75 pharmaceutical and biotechnology companies, generating more than 340 therapeutic programs, of which 40 have entered clinical trials. Our technology has been transferred and implemented at Biogen, GSK, Lilly, Merck, Novo Nordisk, and Takeda. Funded discovery partners include leading pharmaceutical companies, such as Boehringer Ingelheim, Celgene, Genentech, Gilead, Kyowa Hakko Kirin, Novartis, Roche, Sanofi, and others. We have also partnered with many early-stage venture-backed companies, including Amagma, Cullinan Oncology, Dragonfly, Pliant, Tizona, iTeos, and others, as well as mid- size public biopharmaceutical companies such as Acceleron, Alector, Five Prime, Innovent, Jounce, Mersana, Scholar Rock, Seattle Genetics, Surface Oncology, and others.
Our integrated antibody discovery and engineering platform provides unprecedented speed from antigen to purified, full-length human IgGs. We offer fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most demanding standards for affinity, epitope coverage, species cross-reactivity, and developability. We enable our partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.
Needed upon hire
Valid through: 11/10/2020